Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05877599 | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | recruiting | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25) | active not recruiting | Phase 1 | 40 | Arcus Biosciences, Inc.INDUSTRY | 3 | Sep 29, 2026 |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06799065 | First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 218 | Accent TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06888921 | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer(MAIA-ovarian) | recruiting | Phase 1 / Phase 2 | 60 | Compugen LtdINDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT06906471 | A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS | active not recruiting | Phase 1 / Phase 2 | 10 | Antelope Surgical Solutions, IncINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07100847 | Periprostatic Neurolysis in Prostate Cancer | active not recruiting | Phase 1 | 21 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07402915 | Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 1 | 32 | AstraZenecaINDUSTRY | 4 | Sep 29, 2026 | clinicaltrials |
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07705035 | DBC-664 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 210 | Duboce Biopharmaceuticals, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07770802 | Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer | recruiting | Phase 1 | 15 | Hangzhou Huasai Biomedicine Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04235777 | Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies | active not recruiting | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04662580 | ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer(ARX517) | active not recruiting | Phase 1 | 183 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05562830 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | recruiting | Phase 1 / Phase 2 | 48 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT05867251 | Study of AVZO-021 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 430 | Avenzo Therapeutics, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT06586957 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 238 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | recruiting | Phase 1 | 260 | IDEAYA BiosciencesINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07421700 | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 132 | PfizerINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT07594106 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 265 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02123758 | A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 57 | Aragon Pharmaceuticals, Inc.INDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT03460977 | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | recruiting | Phase 1 | 453 | PfizerINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT03564340 | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | recruiting | Phase 1 / Phase 2 | 890 | Regeneron PharmaceuticalsINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT05316155 | Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | active not recruiting | Phase 1 / Phase 2 | 235 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT05922930 | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06218914 | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | recruiting | Phase 1 | 108 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06800313 | Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 190 | Janssen Research & Development, LLCINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06801236 | Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 88 | Acerand Therapeutics (Hong Kong) LimitedINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07181161 | Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer(SEACLIFF) | recruiting | Phase 1 / Phase 2 | 283 | AstraZenecaINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT07401875 | A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) | recruiting | Phase 1 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07508358 | Vaginal Sildenafil for Primary Dysmenorrhea(SILDYS) | not yet recruiting | Phase 1 | 10 | Kevin HellmanOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07657806 | DEC003M in Prostate Cancer | recruiting | Phase 1 | 110 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07670312 | Evaluation of XYA02 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 190 | XYone Therapeutics, IncINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07748988 | Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 12 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04590326 | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | recruiting | Phase 1 / Phase 2 | 612 | Regeneron PharmaceuticalsINDUSTRY | 5 | Sep 24, 2026 | clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07217496 | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer | not yet recruiting | Phase 1 | 18 | ImmunityBio, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07543055 | A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread | recruiting | Phase 1 | 36 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07711184 | A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer | recruiting | Phase 1 | 320 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT07719361 | A Study in Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 60 | Flare Therapeutics Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07800507 | Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | Yunnan Cancer HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04044859 | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | active not recruiting | Phase 1 | 120 | USWM CT, LLCINDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT06253520 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | active not recruiting | Phase 1 | 210 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06926283 | A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors | recruiting | Phase 1 | 110 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07177937 | A Study of DXC014 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 150 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | recruiting | Phase 1 / Phase 2 | 474 | Bristol-Myers SquibbINDUSTRY | 20 | Sep 23, 2026 | clinicaltrials |
| NCT04963153 | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT05276973 | Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer | active not recruiting | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
Data updated 1 hour agoSource updated Sep 29, 2026source: clinicaltrials